Michael W. Pride, PhD

Executive Director, Vaccine Research and Development
Pfizer

Disclosure: Pfizer (Individual(s) Involved: Self): Employee, Shareholder

Presentation(s):

• 3 - Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older

  Oral Abstract